Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013–2018

Table 3 Time series coefficients and 95% confidence intervals of genetic testing trends by type of health plan coverage

	Commercial n=1,501,828 β^a (95% CI)	Medicaid n=1,516,850 β^a (95% CI)	State employee n=154,529 β^a (95% CI)	Medicare n=519,955 β^a (95% CI)
HBOC testing	0.78 (0.43, 1.13) P-value: <0.001	0.16 (0.02, 0.30) P-value: 0.024	1.62 (0.23, 3.02) P-value: 0.026	0.35 (0.07, 0.62) P-value: 0.020
Lynch syndrome testing	0.20 (0.14, 0.25) P-value: <0.001	-0.15 (-0.36, 0.06) P-value: 0.159 0.01 (0.00, 0.02)^b P-value: 0.045	-0.97 (-1.99, 0.05) P-value: 0.062 0.05 (0.01, 0.10)^b P-value: 0.028	0.21 (0.09, 0.33) P-value: 0.004
Tier 2 molecular pathology procedures^c	0.89 (0.31, 1.47) P-value: 0.005	0.71 (0.26, 1.17) P-value: 0.004	2.34 (1.10, 3.58) P-value: 0.001	0.55 (-5.34, 6.43) P-value: 0.853
Any cancer genetic testing^d	2.24 (1.46, 3.03) P-value: <0.001	0.99 (0.33, 1.66) P-value: 0.006	4.23 (1.53, 6.93) P-value: 0.004	1.82 (-3.93, 7.56) P-value: 0.520

HBOC Hereditary Breast and Ovarian Cancer
^a β represents the linear change per 100,000 persons per quarter
^b Quadratic trend term
^c Tier 2 molecular pathology procedures are based on the complexity of the testing technique and are not specific to a gene or hereditary cancer syndrome
^d Any cancer genetic testing included tests in the HBOC, Lynch syndrome, Tier 2 molecular pathology procedures, and other hereditary cancer syndrome (HCS) panel categories

ISSN: 1897-4287